{"id":915676,"date":"2025-12-03T10:35:28","date_gmt":"2025-12-03T15:35:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-marks-transformational-first-year-as-a-public-company-entering-2026-with-powerful-clinical-and-commercial-momentum\/"},"modified":"2025-12-03T10:35:28","modified_gmt":"2025-12-03T15:35:28","slug":"jupiter-neurosciences-marks-transformational-first-year-as-a-public-company-entering-2026-with-powerful-clinical-and-commercial-momentum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-marks-transformational-first-year-as-a-public-company-entering-2026-with-powerful-clinical-and-commercial-momentum\/","title":{"rendered":"Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum"},"content":{"rendered":"
\n

\n
\n Company advances JOTROL<\/i>
\n <\/b>
\n
\n
\n \u2122<\/i>
\n <\/b>
\n <\/sup>
\n
\n into Phase 2a Parkinson\u2019s trial, launches Nugevia<\/i>
\n <\/b>
\n
\n
\n \u2122<\/i>
\n <\/b>
\n <\/sup>
\n
\n consumer brand, and strengthens financial position<\/i>
\n <\/b>\n <\/p>\n

Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122<\/sup>, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Ros\u00e9n marking Jupiter\u2019s first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026.<\/p>\n

\n Dear Fellow Shareholders,<\/b>\n <\/p>\n

As we celebrate our first full year as a public company, I want to express my deepest gratitude for your belief in Jupiter Neurosciences and the mission we are pursuing. When we completed our IPO in December 2024, we did more than enter the public markets \u2014 we stepped into a new era defined by bold ambition, scientific conviction, and the unwavering pursuit of improving human healthspan and longevity. Over the course of 2025, Jupiter laid a powerful foundation for long-term value creation, executed on every major initiative we committed to, and opened the door to a year of extraordinary opportunity ahead.<\/p>\n

Today, we are not simply a clinical-stage biotechnology company \u2014 we are a neuroscience-driven longevity company with two powerful value creation engines, both rooted in the same breakthrough science. With the advancement of our JOTROL\u2122<\/sup> pharmaceutical platform and the commercial launch of our Nugevia consumer product line, Jupiter is entering 2026 with momentum, clarity, and the infrastructure to accelerate toward meaningful clinical data, revenue growth, and long-term profitability.<\/p>\n

\n FDA Clears IND to Initiate Phase 2a Trial in Parkinson\u2019s Disease<\/b>\n <\/p>\n

In November 2025, the U.S. FDA officially cleared our IND application, authorizing Jupiter to initiate a Phase 2a clinical trial of JOTROL\u2122<\/sup> in Parkinson\u2019s disease, a critical regulatory milestone that positions us to begin patient enrollment in early 2026.<\/p>\n

This milestone is the culmination of years of scientific development and validation demonstrating JOTROL\u2019s nine-fold bioavailability improvement, blood-brain barrier penetration, and compelling neuroprotective effects in the well-established MPTP Parkinson\u2019s model. With Zina Biopharmaceuticals guiding trial protocol and biomarker strategy, and Catalent as our manufacturing partner, we enter 2026 fully prepared to advance this landmark study.<\/p>\n

\n Strengthening Foundation in $8 Trillion Longevity Market<\/b>\n <\/p>\n

In 2025, Jupiter launched Nugevia, a premium longevity supplement line designed to generate near-term revenue while elevating our brand visibility and deepening the market\u2019s understanding of our science.<\/p>\n

Nugevia\u2019s three launch products \u2014 GLO, PWR, and MND \u2014 each integrate our patented JOTROL\u2122<\/sup> platform with synergistic, highly bioavailable ingredients such as NovaSOL\u00ae<\/sup> Astaxanthin, CoQ10, and Curcumin to support skin vitality, mitochondrial energy, and cognitive resilience. Together, they deliver pharmaceutical-grade standards into a consumer market projected to exceed $8 trillion by 2030.<\/p>\n

As we accelerate the commercial roll-out of Nugevia, our marketing efforts are being supported by high-profile brand ambassadors, including golf icon Annika S\u00f6renstam, NBA legend Chris Webber, and internationally recognized biohacker Jean Fallacara, all of whom reinforce the performance-driven identity of the brand.<\/p>\n

After launching a dedicated website (www.nugevia.com<\/a>) in August 2025, we began taking initial pre-orders and established the infrastructure for a recurring subscription-based model, a key component of our path toward profitability.<\/p>\n

\n Strategic Financing Designed for Strength, Flexibility, and Control<\/b>\n <\/p>\n

We recently secured strategic financing agreements with Yorkville Advisors, providing Jupiter with access to up to $20 million in flexible capital to support our Phase 2 Parkinson\u2019s trial and accelerate Nugevia\u2019s commercial expansion.<\/p>\n

This financing is fully controlled by Jupiter, highly flexible, and non-toxic. We determine when capital is accessed, how much capital is accessed, and whether it is accessed at all.<\/p>\n

The SEPA structure allows us to draw only when it is advantageous, providing strength and stability during this pivotal growth stage. The initial pre-paid advance provided immediate capital at a fixed conversion price of $1.50, further demonstrating confidence in our long-term value.<\/p>\n

This capital strategy strengthens Jupiter\u2019s position as we work to complete the Phase 2 Parkinson\u2019s trial, expand our commercial footprint, and support ongoing operations without compromising shareholder interests.<\/p>\n

\n Looking Forward: Our 2025 Vision<\/b>\n <\/p>\n

As we enter 2026, Jupiter is positioned for one of the most important years in our company\u2019s history.<\/p>\n